Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

被引：1
|
作者：
Santos, Allan de Souza
Santos, Herbert Henrique de Melo
Salvino, Marco Aurelio
Silva, Sarah Queiroz
Lucas, Larissa Ferreira
Almeida, Alessandro de M.
Santos, Mariane Melo
Santos, Juliana Andrade
Hungria, Vania T. M.
Arruda, Maria da Gloria B.
Torres, Alex
Crusoe, Edvan De Queiroz
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141438
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
    Loiseau, Herve Avet
    Sonneveld, Pieter
    Moreau, Philippe
    Offner, Fritz
    van der Velden, Vincent H. J.
    Caillot, Denis
    Hulin, Cyrille
    Arnulf, Bertrand
    Corre, Jill
    Mohty, Mohamad
    Karlin, Lionel
    Lambert, Jerome
    Macro, Margaret
    Perrot, Aurore
    Levin, Mark-David
    Klein, Saskia K.
    Stoppa, Anne-Marie
    Delforge, Michel
    Zweegman, Sonja
    Jie, Kon-Siong
    Van De Donk, Niels W. C. J.
    Krevvata, Maria
    Rigat, Fabio
    Yang, Shiyi
    Vanquickelberghe, Veronique
    de Boer, Carla
    Kampfenkel, Tobias
    Vermeulen, Jessica
    Wuilleme, Soraya
    Broyl, Annemiek
    Bene, Marie C.
    BLOOD, 2021, 138
  • [32] Efficacy of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    Hulin, Cyrille
    Arnulf, Bertrand
    Corre, Jill
    Garderet, Laurent
    Karlin, Lionel
    Lambert, Jerome
    Macro, Margaret
    Perrot, Aurore
    Sonneveld, Pieter
    Levin, Mark-David
    Klein, Saskia
    Chiu, Christopher
    Pei, Lixia
    De Boer, Carla
    Kampfenkel, Tobias
    Wuilleme, Soraya
    Bene, Marie-Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Daratumumab (DARA) plus Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
    Corre, Jill
    Vincent, Laure
    Moreau, Philippe
    Hebraud, Benjamin
    Hulin, Cyrille
    Bene, Marie
    Broijl, Annemiek
    Caillot, Denis
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Perrot, Aurore
    Zweegman, Sonja
    Hua, Winnie
    Krevvata, Maria
    Vanquickelberghe, Veronique
    Tuozzo, Alba
    Rowe, Melissa
    Carson, Robin
    Wuilleme, Soraya
    Avet-Loiseau, Herve
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S29 - S30
  • [34] Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia
    Cesar Solano, Julio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S248 - S248
  • [35] Effect of Daratumumab (DARA), Cyclophosphamide (C), T Halidomide (T) and Dexamethasone (D) combination of Lymphocyte populations of transplant eligible newly diagnosed Multiple Myeloma patients
    Santos, Allan
    Santos, Herbert
    Salvino, Marco
    Santos, Juliana
    Queiroz, Sarah
    Lucas, Larissa
    Almeida, Alessandro
    Santos, Mariane
    Leal, JOanna
    Arruda, Maria da Gloria
    Torres, Alex
    Crusoe, Edvan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S75 - S75
  • [36] Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)
    Vishwamitra, Deeksha
    Mantis, Christine
    Haribhai, Dipica
    Uziel, Tamar
    Leverson, Joel D.
    Pauff, James M.
    Bueno, Orlando F.
    Maciag, Paulo C.
    Ross, Jeremy A.
    BLOOD, 2019, 134
  • [37] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
    Ocio, Enrique M.
    Rodriguez Otero, Paula
    Bringhen, Sara
    Oliva, Stefania
    Nogai, Axel
    Attal, Michel
    Moreau, Philippe
    Kanagavel, Dheepak
    Fitzmaurice, Thomas F.
    Wu, Junlong
    Martinez Lopez, Joaquin
    BLOOD, 2018, 132
  • [38] Daratumumab (DARA) plus Bortezomib/ Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
    Moreau, Philippe
    Hulin, Cyrille
    Perrot, Aurore
    Arnulf, Bertrand
    Belhadj, Karim
    Benboubker, Lotfi
    Zweegman, Sonja
    Caillon, Helene
    Caillot, Denis
    Avet-Loiseau, Herve
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Sonntag, Cecile
    Fontan, Jean
    Mohty, Mohamad
    Jie, Kon-Siong
    Karlin, Lionel
    Kuhnowski, Frederique
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Orsini-Piocelle, Frederique
    Roussel, Murielle
    de Colella, Jean Marc Schiano
    van de Donk, Niels W. C. J.
    Wuilleme, Soraya
    Broijl, Annemiek
    Touzeau, Cyrille
    Tiab, Mourad
    Marolleau, Jean-Pierre
    Meuleman, Nathalie
    Vekemans, Marie-Christiane
    Westerman, Matthijs
    Klein, Saskia K.
    Levin, Mark-David
    Offner, Fritz
    Escoffre-Barbe, Martine
    Eveillard, Jean-Richard
    Garidi, Reda
    Hua, Winnie
    Wang, Jianping
    Tuozzo, Alba
    de Boer, Carla J.
    Rowe, Melissa
    Vanquickelberghe, Veronique
    Carson, Robin
    Vermeulen, Jessica
    Corre, Jill
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S560 - S561
  • [39] MICRORNA (MIRNA) EXPRESSION PROFILING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TREATED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (CRD)
    Jasielec, J. K.
    Chen, J. L.
    Rosebeck, S.
    Dytfeld, D.
    Griffith, K.
    Alonge, M.
    McDonnell, K.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Jakubowiak, A.
    HAEMATOLOGICA, 2014, 99 : 366 - 366
  • [40] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
    Sonneveld, Pieter
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Quach, Hang
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels W. C. J.
    Katodritou, Eirini
    Schjesvold, Fredrik
    Sureda Balari, Anna
    Rosinol, Laura
    Delforge, Michel
    Roeloffzen, Wilfried
    Driessen, Christoph
    Vangsted, Annette
    Einsele, Hermann
    Spencer, Andrew
    Hajek, Roman
    Jurczyszyn, Artur
    Lonergan, Sarah
    Liu, Yanfang
    Wang, Jianping
    Vieyra, Diego
    van Brummelen, Emilie M. J.
    Vanquickelberghe, Veronique
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Boccadoro, Mario
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
12345